Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer

BACKGROUND: PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients with BRCA mutations, and their efficacy is even more limited in triple-negative breast cancer (TNBC) due to clinical primary and acquired resistance. Here, we found that the efficacy of the PARPi olaparib in TNBC c...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Exp Clin Cancer Res
Auteurs principaux: Zhu, Xiuzhi, Chen, Li, Huang, Binhao, Li, Xiaoguang, Yang, Liu, Hu, Xin, Jiang, Yizhou, Shao, Zhimin, Wang, Zhonghua
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2021
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8028839/
https://ncbi.nlm.nih.gov/pubmed/33832512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-021-01930-w
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires